These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 36700149)
1. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529). Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149 [TBL] [Abstract][Full Text] [Related]
2. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1. Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W Viruses; 2023 May; 15(6):. PubMed ID: 37376552 [TBL] [Abstract][Full Text] [Related]
4. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385 [TBL] [Abstract][Full Text] [Related]
5. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern. Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063 [TBL] [Abstract][Full Text] [Related]
6. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510 [TBL] [Abstract][Full Text] [Related]
7. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes. Sun Z; Wang L; Li L; Sun Y; Zhang D; Zhou S; Li Y; Li X; Qiao H; Cui Q; Lan Z; Meng X; Xu J; Geng Y; Dai Y J Struct Biol; 2023 Sep; 215(3):107996. PubMed ID: 37419228 [TBL] [Abstract][Full Text] [Related]
9. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization. Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467 [TBL] [Abstract][Full Text] [Related]
10. Rapid and Quantitative Wu W; Tan X; Zupancic J; Schardt JS; Desai AA; Smith MD; Zhang J; Xie L; Oo MK; Tessier PM; Fan X Anal Chem; 2022 Mar; 94(10):4504-4512. PubMed ID: 35238533 [TBL] [Abstract][Full Text] [Related]
11. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732 [TBL] [Abstract][Full Text] [Related]
12. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196 [TBL] [Abstract][Full Text] [Related]
13. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant. Zheng L; Wang H; Liu X; Xu C; Tian M; Shi G; Bai C; Li Z; Wang J; Liu S J Med Virol; 2024 Mar; 96(3):e29528. PubMed ID: 38501378 [TBL] [Abstract][Full Text] [Related]
14. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants. He L; Wu Q; Zhang Z; Chen L; Yu K; Li L; Jia Q; Wang Y; Ni J; Wang C; Li Q; Zhai X; Zhao J; Liu Y; Fan R; Li YP Mol Pharm; 2024 Aug; 21(8):3866-3879. PubMed ID: 38920116 [TBL] [Abstract][Full Text] [Related]
15. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization. Yang J; Lin S; Chen Z; Yang F; Guo L; Wang L; Duan Y; Zhang X; Dai Y; Yin K; Yu C; Yuan X; Sun H; He B; Cao Y; Ye H; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G PLoS Pathog; 2023 Nov; 19(11):e1011804. PubMed ID: 38033141 [TBL] [Abstract][Full Text] [Related]
16. Superimmunity by pan-sarbecovirus nanobodies. Xiang Y; Huang W; Liu H; Sang Z; Nambulli S; Tubiana J; Williams KL; Duprex WP; Schneidman-Duhovny D; Wilson IA; Taylor DJ; Shi Y Cell Rep; 2022 Jun; 39(13):111004. PubMed ID: 35738279 [TBL] [Abstract][Full Text] [Related]
17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
18. Structural basis of nanobodies neutralizing SARS-CoV-2 variants. Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082 [TBL] [Abstract][Full Text] [Related]
20. Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. Su Q; Shi W; Huang X; Wan Y; Li G; Xing B; Xu ZP; Liu H; Hammock BD; Yang X; Yin S; Lu X Cells; 2022 Oct; 11(21):. PubMed ID: 36359751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]